 |
submitted by /u/mvea [link] [comments] |
The world could be free of malaria - one of the oldest and deadliest diseases to affect humanity - within a generation, a major report says. Forty-one of the world's leading malaria experts - ranging from scientists to economists - have concluded that it can be done by 2050.
Malaria can be eradicated by 2050, say global experts
Malaria can be eradicated by 2050, say global experts
Reuters: Health
Malaria can be eradicated within a generation, global health experts have said.
Reuters: Health
Malaria can be eradicated within a generation, global health experts have said.
Slovakian biotech firm signals tentative Alzheimer's drug hope
Slovakian biotech firm signals tentative Alzheimer's drug hope
Reuters: Health
An Alzheimer's vaccine developed by a privately held Slovakian biotech firm showed early signs of efficacy in a mid-stage trial, a rare step forward in the fight against the brain-wasting disease, the company said on Monday. 
Reuters: Health
An Alzheimer's vaccine developed by a privately held Slovakian biotech firm showed early signs of efficacy in a mid-stage trial, a rare step forward in the fight against the brain-wasting disease, the company said on Monday.
U.S. doctors more likely to prescribe opioid painkillers after low-risk surgery, suggests a new study (n=129,379), which found that 75 percent of patients in the US filled prescriptions within a week of four low-risk surgeries, more than other countries. That's compared to only 11 percent in Sweden.
 |
submitted by /u/mvea [link] [comments] |
Slovakian biotech firm in tentative Alzheimer's drug hope
Slovakian biotech firm in tentative Alzheimer's drug hope
Reuters: Health
An Alzheimer's vaccine developed by a privately held Slovakian biotech firm showed early signs of efficacy in a mid-stage trial, in a rare step forward in the fight against the brain-wasting disease, the company said on Monday. 
Reuters: Health
An Alzheimer's vaccine developed by a privately held Slovakian biotech firm showed early signs of efficacy in a mid-stage trial, in a rare step forward in the fight against the brain-wasting disease, the company said on Monday.
Lilly's targeted RET drug shrinks tumors in lung cancer trial
Lilly's targeted RET drug shrinks tumors in lung cancer trial
Reuters: Health
Eli Lilly and Co's LOXO-292, a experimental cancer drug the company acquired in January as part of its $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70% of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene. 
Reuters: Health
Eli Lilly and Co's LOXO-292, a experimental cancer drug the company acquired in January as part of its $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70% of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene.
Subscribe to:
Comments (Atom)